NTX-001

COMBINATION_PRODUCT4 trials

Sponsors

Neuraptive Therapeutics Inc., Major Extremity Trauma Research Consortium

Conditions

Facial ParalysisPeripheral Nerve InjuriesPeripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves

Phase 2

Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries

CompletedNCT04572906

Neuraptive Therapeutics Inc.Peripheral Nerve Injuries

Start: 2020-09-25End: 2024-06-27Updated: 2024-11-20

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

Active, not recruitingNCT04789044

Major Extremity Trauma Research ConsortiumPeripheral Nerve Injuries

Start: 2023-06-01End: 2028-10-01Target: 40Updated: 2026-09-10

A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

TerminatedNCT05293522

Neuraptive Therapeutics Inc.Facial Paralysis

Start: 2022-07-12End: 2023-08-22Updated: 2023-09-11

Unknown Phase

NTX-001 to Repair Peripheral Nerve Transection(s)

Neuraptive Therapeutics Inc.Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves

Updated: 2026-07-08